Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9. It is employed in studies targeting transcription regulation in cancer cells, where CDK9 plays a key role in promoting cell survival and proliferation. The compound shows promise in preclinical models for treating hematological malignancies and solid tumors due to its ability to suppress oncogenic transcription. Its structure allows for high binding affinity and improved pharmacokinetic properties, making it a valuable tool compound in kinase inhibitor development and a potential candidate for further optimization in anticancer drug discovery.